AR012035A1 - Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico - Google Patents

Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico

Info

Publication number
AR012035A1
AR012035A1 ARP980100837A ARP980100837A AR012035A1 AR 012035 A1 AR012035 A1 AR 012035A1 AR P980100837 A ARP980100837 A AR P980100837A AR P980100837 A ARP980100837 A AR P980100837A AR 012035 A1 AR012035 A1 AR 012035A1
Authority
AR
Argentina
Prior art keywords
prostate cancer
polypeptide
detecting
joins
equipment
Prior art date
Application number
ARP980100837A
Other languages
English (en)
Spanish (es)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR012035A1 publication Critical patent/AR012035A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G01N33/57434—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP980100837A 1997-02-25 1998-02-25 Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico AR012035A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659697A 1997-02-25 1997-02-25
US90480997A 1997-08-01 1997-08-01
US2074798A 1998-02-09 1998-02-09

Publications (1)

Publication Number Publication Date
AR012035A1 true AR012035A1 (es) 2000-09-27

Family

ID=27361502

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100837A AR012035A1 (es) 1997-02-25 1998-02-25 Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico

Country Status (13)

Country Link
US (1) US6887660B2 (enExample)
EP (2) EP0972201B1 (enExample)
JP (4) JP3844366B2 (enExample)
AR (1) AR012035A1 (enExample)
AT (1) ATE302414T1 (enExample)
BR (1) BR9807734A (enExample)
CA (1) CA2281954A1 (enExample)
CO (1) CO4870792A1 (enExample)
DE (1) DE69831222T2 (enExample)
DK (1) DK0972201T3 (enExample)
ES (1) ES2248891T3 (enExample)
IL (1) IL131539A0 (enExample)
WO (1) WO1998037418A2 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7270980B2 (en) * 1997-02-25 2007-09-18 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
CN1195851C (zh) 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6048970A (en) * 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP2080802B1 (en) 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
WO1999062942A2 (en) * 1998-06-01 1999-12-09 Urogenesys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
KR20010083111A (ko) * 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
CA2344552A1 (en) * 1998-10-02 2000-04-13 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
EP1724351A3 (en) * 1999-03-11 2007-11-14 Mount Sinai Hospital Human Kallikrein-like genes
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
CO5450246A1 (es) * 1999-07-13 2004-10-29 Smithkline Beecham Corp Vacuna
US6720146B2 (en) 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6613515B1 (en) 1999-09-10 2003-09-02 Corixa Corporation Ovarian tumor sequences and methods of use therefor
WO2001018046A2 (en) * 1999-09-10 2001-03-15 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6617109B1 (en) 1999-09-10 2003-09-09 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
GB9922835D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Novel compounds
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
JP2003528584A (ja) * 1999-10-07 2003-09-30 シエーリング アクチエンゲゼルシャフト Ｐｒｏｓｔ０７ポリペプチドをコードするｄｎａ
CA2391369A1 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1261708A2 (en) * 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP2004504808A (ja) * 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
RU2276672C2 (ru) * 2000-04-10 2006-05-20 Институт Биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова Российской Академии Наук Антитело к фактору hldf, способ его получения (варианты), пептид с антигенными и нк-гидролизующими свойствами и способ диагностики анапластического состояния клетки человека
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
DK2266603T3 (da) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
US7037652B2 (en) 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP2316976A1 (en) 2000-11-28 2011-05-04 Wyeth LLC Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1792912A3 (en) * 2002-04-02 2007-08-29 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004013279A2 (en) * 2002-05-14 2004-02-12 Fidelity Systems, Inc. Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
US7276408B2 (en) * 2003-10-08 2007-10-02 Texas Instruments Incorporated Reduction of dopant loss in a gate structure
WO2005062977A2 (en) * 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
CA2563735C (en) 2004-04-22 2020-07-14 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
EP2675473A1 (en) 2011-02-15 2013-12-25 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2017180420A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
CA3023271A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
CN117120087A (zh) 2020-12-23 2023-11-24 高级健康研究所 茄尼醇疫苗助剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851764A (en) 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
WO1993014753A1 (en) 1992-01-27 1993-08-05 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives and methods for their use
WO1993014775A1 (en) * 1992-01-31 1993-08-05 Wright George L Jr Monoclonal antibody pd41 and antigen associated with prostate adenocarcinomas
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
JP4204642B2 (ja) 1992-11-05 2009-01-07 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺に特異的な膜抗原
ATE303160T1 (de) 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
EP0804593A1 (en) 1994-05-10 1997-11-05 Mayo Foundation For Medical Education And Research Recombinant hk2 polypeptide
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
US20020081580A1 (en) 2002-06-27
IL131539A0 (en) 2001-01-28
JP2008249727A (ja) 2008-10-16
DE69831222D1 (de) 2005-09-22
EP1630235A2 (en) 2006-03-01
JP2007114212A (ja) 2007-05-10
CO4870792A1 (es) 1999-12-27
CA2281954A1 (en) 1998-08-27
DK0972201T3 (da) 2006-01-02
JP2001513886A (ja) 2001-09-04
BR9807734A (pt) 2000-10-31
ES2248891T3 (es) 2006-03-16
WO1998037418A2 (en) 1998-08-27
JP2006201187A (ja) 2006-08-03
ATE302414T1 (de) 2005-09-15
WO1998037418A3 (en) 1999-02-25
JP3844366B2 (ja) 2006-11-08
DE69831222T2 (de) 2006-07-13
EP0972201B1 (en) 2005-08-17
EP1630235A3 (en) 2009-05-27
US6887660B2 (en) 2005-05-03
EP0972201A2 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
AR012035A1 (es) Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico
US5362852A (en) Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
KR870700100A (ko) 최소한 일부분이 알려진 뉴클레오티드 암호서열 또는 아미노산 서열을 갖는 프로테인 또는 펩티드에 상보적인 폴리펩티드와 이것의 디자인 방법
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
AR038568A1 (es) Anticuerpos anti-a beta y su uso
EE05496B1 (et) Antikeha, mis seob osteoprotegeriini siduvat valku
CA2286304A1 (en) Pca3, pca3 genes, and methods of use
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
BR9811039A (pt) Citocina de mamìferos: interleucina-b30 e reagentes relacionados
RU2011103199A (ru) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
ID28299A (id) Protein-protein reseptor seperti toll manusia metoda-metoda dan reagen-reagen yang berhubungan
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
CA2344590A1 (en) Treatment of inflammatory disease
PE20021098A1 (es) ANTICUERPOS ESPECIFICOS DE CD44v6
KR850006550A (ko) 단백질의 제조방법
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
AR010139A1 (es) Una molecula que tiene una region de union de antigeno especifica para un epitope del antigeno fas, un anticuerpo, adn que codifica cualquier porcionindividual del polipeptido de dicha molecula, un vector de adn recombiante, una celula huesped, e coli, el uso de una molecula para la preparacion de u
WO2003104429B1 (en) Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
BR9910725A (pt) Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14

Legal Events

Date Code Title Description
FG Grant, registration